Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Diabetic retinopathy Stories

2014-04-17 15:26:52

Indiana University researchers have detected new early-warning signs of the potential loss of sight associated with diabetes. This discovery could have far-reaching implications for the diagnosis and treatment of diabetic retinopathy, potentially impacting the care of over 25 million Americans. "We had not expected to see such striking changes to the retinas at such early stages," said Ann Elsner, professor and associate dean in the IU School of Optometry and lead author of the study. "We...

2014-04-17 08:28:26

ST. LOUIS, April 17, 2014 /PRNewswire/ -- Did you know women are more likely to suffer from visual impairments like Age-related Macular Degeneration, Glaucoma, Diabetic Retinopathy, and Cataracts than men? According to the National Eye Institute (NEI), out of the 3.6 million Americans over 40 who suffer from optical damage or injury -- including blindness -- 2.3 million are women. That's why EyePromise is supporting Women's Eye Health and Safety Month throughout April. Logo -...

2014-04-08 12:25:55

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Diabetic Macular Edema Global Clinical Trials Review, H2, 2013Diabetic Macular Edema Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic...

2014-04-01 16:25:30

Welch brings more than 25 years of leadership and global healthcare industry expertise to IRIS as the company expands its regional and national footprint PENSACOLA, Fla., April 1, 2014 /PRNewswire/ -- IRIS: Intelligent Retinal Imaging Systems, the country's preeminent cloud-based retinal screening technology provider, announced today that Pat Welch has joined its leadership team as Vice President of Healthcare Accounts. "Pat brings to the IRIS team more than 25 years of in-depth,...

2014-03-26 11:32:37

New research in the FASEB Journal suggests that the complement system allows the body to identify abnormal vessels and specifically target them for removal without damaging healthy cells A new report published online in The FASEB Journal may lead the way toward new treatments or a cure for a common cause of blindness (proliferative retinopathies). Specifically, scientists have discovered that the body's innate immune system does more than help ward off external pathogens. It also helps...

2014-03-24 12:30:49

LONDON, March 24, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Analysis of the US Retinal Therapeutics Market Improvements in Administration and Efficacy Drive GrowthSince the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research...

2014-03-10 04:21:04

LEUVEN, Belgium, March 10, 2014 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a EUR3 million grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant funding will be used by ThromboGenics to support research into potential new biotherapeutics for the...

2014-03-06 08:29:58

DALLAS, March 6, 2014 /PRNewswire-iReach/ -- ReportsnReports.com adds "U.S. Market for Diagnostic Opthalmic Devices" & "U.S. Market and Survey for Retinopathy Screening Devices" reports to its research database. (Photo: http://photos.prnewswire.com/prnh/20140306/MN77154) The market for diagnostic ophthalmic devices continues to expand, driven by strong growth in revenue from optical coherence tomographers (OCTs). In 2013, the market for diagnostic ophthalmic devices continued...

2014-03-05 08:28:36

VANCOUVER, March 5, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month...

2014-03-03 04:22:41

TARRYTOWN, N.Y., March 3, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA(®) (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare (MHLW). "Clinically significant DME is a leading cause of vision loss in the working-age...